Spherix Global Insights said AbbVie’s Skyrizi has quickly blasted past Eli Lilly’s Omvoh in ulcerative colitis, ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

Afton Scientific, a CDMO, plans to shell out $200 million to expand its manufacturing plant in Charlottesville, Virginia, as ...

After Kaléo unveiled a “redesign” of the in-office commercial team for its EpiPen rival Auvi-Q at the start of the month, the ...

Courtney Walker, Chief Growth Officer at MMC and RXMosaic, discusses the evolving role of communicators and the future of the ...

Respiratory medicine is one frontier of the global healthcare landscape which has undergone significant transformations in ...

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...

After announcing the closure of its biggest manufacturing site Sunday due to flooding caused by Hurricane Helene, Baxter ...

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...

BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...